Pippard M J, Jackson M J, Hoffman K, Petrou M, Modell C B
Scand J Haematol. 1986 May;36(5):466-72. doi: 10.1111/j.1600-0609.1986.tb02282.x.
The iron chelating ability and potential toxicity of subcutaneous infusions of the calcium and zinc salts of diethylene triamine penta-acetic acid (DTPA) have been assessed in metabolic balance studies in 2 iron-loaded thalassaemic patients. Infusions of calcium DTPA were locally well tolerated and the drug was as effective as desferrioxamine in mobilising iron. However, daily infusions in the 1st patient also produced symptomatic zinc depletion which could not be controlled by simultaneous oral zinc supplements. Zinc DTPA proved ineffective as an iron chelator, but zinc balance could be maintained in the 2nd patient by combining intermittent (every 4 d) use of calcium DTPA with oral zinc supplements. Combined studies with desferrioxamine and calcium DTPA showed the drugs to have additive effects, probably as a result of the chelation of iron from different body sites.
在对两名铁负荷过重的地中海贫血患者进行的代谢平衡研究中,评估了皮下输注二乙烯三胺五乙酸(DTPA)钙盐和锌盐的铁螯合能力及潜在毒性。输注DTPA钙时局部耐受性良好,该药物在动员铁方面与去铁胺效果相同。然而,第一名患者每日输注也导致了有症状的锌缺乏,同时口服锌补充剂无法控制这种情况。DTPA锌作为铁螯合剂被证明无效,但通过间歇性(每4天一次)使用DTPA钙并结合口服锌补充剂,第二名患者的锌平衡得以维持。去铁胺和DTPA钙的联合研究表明这两种药物具有相加作用,这可能是由于从不同身体部位螯合铁的结果。